BIOVF News and Press, Swedish Orphan Biovit Ord From 02/13/20

The following slide deck was published by Swedish Orphan Biovitrum AB (publ) in conjunction with their 2019 Q4 earnings Read more ...

STOCKHOLM , Feb. 13, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ)  (Sobi™) today announces its results for the fourth quarter and full-year 2019. Revenue growth for the full-year was 56 per cent with revenue of SEK 14,248 M . Adjusted EBITA was SEK 6,145 M , resu...

STOCKHOLM , Feb. 4, 2020 /PRNewswire/ -- On 13 February, at 08:00 CET , Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the fourth quarter and full-year 2019. Financial analysts and media are invited to participate in a telephone conference, which will inc...

STOCKHOLM , Dec. 21, 2019 /PRNewswire/ -- Dova Pharmaceuticals, Inc., a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™) has been granted Orphan Drug Designation [1]  (ODD) by the US Food and Drug Administration (FDA) for avatrombopag for the potential tre...

STOCKHOLM , Dec. 9, 2019 /PRNewswire/ -- Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™), presented additional analyses from the phase 3 study - core and extension phase - with avatrombopag (AVA) for the treatment of immune thrombocytop...

STOCKHOLM , Dec. 5, 2019 /PRNewswire/ -- Sobi™ and its wholly owned subsidiary Dova Pharmaceuticals, will present new data from studies with avatrombopag for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) as well as patients with chronic immune...

Biotech Pulse Biotech finally has a pulse. The improving appetite for risk has resuscitated the moribund biotechs and pharma (biopharma) groups. The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have begun their advance from their year-to-date lows recorded earlier in Octo...

Swedish Orphan Biovitrum AB (publ) (BIOVF) Q3 2019 Earnings Conference Call October 31, 2019, 05:00 AM ET Company Participants Guido Oelkers - CEO Henrik Stenqvist - CFO Milan Zdravkovic - Head of Research & Development and Chief Medical Officer Conference Call Participant...

The following slide deck was published by Swedish Orphan Biovitrum AB (publ) in conjunction with their 2019 Q3 earnings Read more ...

STOCKHOLM , Oct. 31, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces its results for the third quarter 2019. Revenue growth in the quarter was 27 per cent with revenue of SEK 2,930 M (2,315). EBITA was SEK 1,099 M , resulting in an EBITA margin ...